Compare LAW & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | AKBA |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.0M | 251.0M |
| IPO Year | 2021 | 2014 |
| Metric | LAW | AKBA |
|---|---|---|
| Price | $3.76 | $1.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $8.00 | $4.67 |
| AVG Volume (30 Days) | 245.0K | ★ 5.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.58 | ★ 93.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,849,000.00 | N/A |
| Revenue This Year | $11.23 | N/A |
| Revenue Next Year | $10.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $2.45 | $0.82 |
| 52 Week High | $9.11 | $4.08 |
| Indicator | LAW | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 51.98 | 57.95 |
| Support Level | $3.32 | $0.85 |
| Resistance Level | $3.84 | $1.56 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 79.84 | 66.83 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.